1. Clinical Rubik’s Cube Opportunities and Challenges in Global R&D Studies: Example of Hungary Dr. Aleksandar Skuban2009 2. Opportunities multiply as they are seized.…

1. How Green was my Process ?: Case Studies of the Role of Process Chemistry in Drug Development Steven A. Weissman (Ph.D. ’87) Tufts University 29March 2004 “ Industrial…

1. Journal of Health Economics 22 (2003) 151–185The price of innovation: new estimates of drug development costsJoseph A. DiMasi a,∗ , Ronald W. Hansen b , Henry G. Grabowski…

1. Supplementary Protection Certificates - targets for litigationDr Duncan Curley Director, Innovate Legalwww.innovatelegal.co.uk C5 Pharma & Bio Patent Litigation Conference…

Slide 1© IFPMA 2009 IFPMA to WHO EWG 12 Jan 09 1 Alicia D. Greenidge, Director General, IFPMA WHO Expert Working Group, Geneva, 12 Jan 2009 IFPMA Presentation to WHO Expert…

Slide 1Infrastructures For Information Inc. The Collaborative XML Content Company Content Company Slide 2 The Collaborative XML Content Company Specializing in the Authoring…

Slide 1Challenges for the Research-Based Industry Review of New Drug Development Kenneth I Kaitin, Ph.D. Director, Tufts Center for the Study of Drug Development Prof. of…

1 Dr. Praveen Balimane Senior staff fellow Division of Clinical Pharmacology-1 at OCP/OTS/CDER/FDA 2015 SLAS ADMET SPECIAL INTEREST GROUP MEETING Washington DC Moderator:…

PowerPoint Presentation Optimizing Protocol Planning, Feasibility, and Site Selection through an Integrated View of Clinical Trial Operations and Other Data Sources Elisa…

1. What Do Doctors Think About Biosimilars? Powered by Small World Social www.biolink.us 2. In March 2015, the Alliance for Safe Biologic Medicines (ASBM), released results…